PATENT CLAIM ANALYSIS

Application Number: 16227820
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "343000"]

Abstract:
The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

Claim (Index 4):
The method of  claim 3 , wherein the EGFR inhibitor is selected from the group consisting of panitumumab, erlotinib, pharmaceutically acceptable salts thereof, and combinations thereof.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.48276
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15011377', '15011420', '15598181', '15598160', '14821931']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8481817278926127
- 35 USC 102 Novelty (BERT): 0.5893387607340692
- Combined Prediction Score: 0.8222974311767584
- Mean Citation Score: 513.4798400000002
- Max Citation Score: 595.12555
- Similarity Product: 389.2210038693249

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test